Avid Bioservices Inc (CDMO)

[entdoc]

Paul and Volgoat, current "chimeric" Bavi half-life is 30 hours (50% excreted in that time). Dosing schedule in trials has been weekly, so assuming a more "steady-state" blood level would be desirable in some applications, such as combo irradiation-Bavi treatment, and even some chemotherapy regimens.
As you know, in some cases Bavi may best be used after chemo, between chemo rounds, or as a primer. Bavi is being used as an immunological stimulant, the same category as BCG vaccine which recruits anti-TB antibodies which also attack some tumors. I can assure you that Bavi as an immunostimulant is Bavi's final, best, or highest use, and although naked Bavi immunostimulant properties are a curiosity and a bonus, the platform is not going to get stuck in that iteration. No question! It has gotten attention in med-scientific circles. Not like Martha Stewart and Sam Waksal dif for ImClone and Erbitux, but Bavi has crashed the MAB clique, and anti-phosphatidyl-this and that is here to stay. Humanized Bavi, then, is not a curiosity that is unneeded. It will probably be dispensed within the decade in a nasal aerosol similar to nasal steroids. And that is huge. "The humanized antibody will also be evaluated as a carrier for therapeutic agents for vascular targeting applications." Dr. Tarran Jones, CEO of AERES, said, "We are delighted to have been able to provide Peregrine with a humanized version of its 3G4 antibody".
It is not in the cards that "chimeric Bavi" is the final and best iteration of the invention, and equally unlikely that PS is going to be the ultimate or only effective target since there are several different aminophospholipid flipped sites on surface membranes of virally n